What is it used for?
BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) . BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. This indication …BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) . BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. This indication …
Read the primary sourceThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Product details
- Active ingredient
- zanubrutinibzanubrutinib
- Form and strength
- CAPSULE · 80 mg; TABLET, FILM COATED · 160 mgCAPSULE · 80 mg; TABLET, FILM COATED · 160 mg
- Manufacturer / applicant
- BEONE MEDICINES USA, INC.BEONE MEDICINES USA, INC.
Capsules: Each 80 mg capsule is a size 0, white to off-white opaque capsule marked with "ZANU 80" in black ink. Tablets: 160 mg, blue, oval, film-coated tablets debossed with "zanu" on one side and functional scoring on …Capsules: Each 80 mg capsule is a size 0, white to off-white opaque capsule marked with "ZANU 80" in black ink. Tablets: 160 mg, blue, oval, film-coated tablets debossed with "zanu" on one side and functional scoring on …
Safety and clinical review
- HemorrhageHemorrhage
- InfectionsInfections
- CytopeniasCytopenias
- Second Primary MalignanciesSecond Primary Malignancies
- Cardiac ArrhythmiasCardiac Arrhythmias
- Hepatotoxicity, Including Drug-Induced Liver InjuryHepatotoxicity, Including Drug-Induced Liver Injury
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Read the primary sourcePrepare your enquiry
Include the brand or generic name, strength, dosage form, requested quantity and country where care is needed. You can attach a prescription when you continue.
Questions patients ask
What is BRUKINSA used for?
BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) . BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. This indication …BRUKINSA is indicated for the treatment of adult patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. This indication is approved under accelerated approval based on overall response rate . Continued approval for this indication may be contingent upon verification and description of clinical benefit in a confirmatory trial. BRUKINSA is indicated for the treatment of adult patients with Waldenström's macroglobulinemia (WM) . BRUKINSA is indicated for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL) who have received at least one anti–CD20-based regimen. This indication …
This source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.
Which formulation of BRUKINSA should I ask about?
CAPSULE · 80 mg; TABLET, FILM COATED · 160 mgCAPSULE · 80 mg; TABLET, FILM COATED · 160 mg
Read the primary sourceWhat determines the price of BRUKINSA?
A current quote depends on the exact presentation, quantity, provider and access arrangements. A catalogue entry is not a stock or delivery promise. Medical charges are paid to the provider, separately from coordination fees.
What should I check before using BRUKINSA?
Ask your clinician to review the complete label, medical history, other medicines, allergies, pregnancy or breastfeeding and any required monitoring. Do not start, stop or change treatment from this page.
Sources and review scope
FDA prescribing informationThis source does not establish current stock, import permission or personal eligibility in China. The treating clinician and provider must confirm these separately.